Thnh phn chnh sn phm L-Glutathione (500 mg): Cht chng oxy ha mnh gip c ch sn sinh melanin nguyn nhn gy sm, nm v tn nhang
107 ShiuM
Bagavant H, Araszkiewicz AM, Ingram JK, et al
sitagliptin Sitagliptin Trade Name: Januvia Drug Class: oral hypoglycemics Mechanism of Action: An inhibitor of dipeptidyl peptidase-4 (DPP-4), a protease that degrades the incretin GLP-1 Incretins are hormones released from the GI tract in response to nutrient ingestion Incretins potentiate glucose-stimulated insulin secretion from beta cells in the pancreas As a result of inhibiting DPP-4, increased or prolonged GLP-1 levels are able to potentiate the secretion of insulin by the pancreas The effect produced by DPP-4 inhibitors is dependent on endogenous GLP-1 levels, and produce a modest effect on GLP-1 activity compared to giving GLP-1 receptor agonists (hence DPP-4 inhibitors do not have the same impact to produce weight loss as GLP-1 agonists)
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for type 2 diabetes management but increasingly prescribed for weight management in adults with obesity or overweight with related health conditions
Co-Q10 resides within the mitochondria of cells, where life-sustaining, energy-producing processes take place
